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Introduction
Cancer cells exhibit at least 2 distinctive metabolic traits: increased 
glycolytic rate, and increased capacity against oxidative stress. 
Cancer cells, even in the presence of O2, preferentially utilize gly-
colytic fermentation to generate energy, a phenomenon known as 
the Warburg effect (1). Although less energy efficient, aerobic gly-
colysis coordinates other metabolic pathways for maximal produc-
tion of macromolecules and antioxidants. One may ask why more 
macromolecules are needed by cancer cells. The answer lies in 
the fact that cancer cells need nucleotides for DNA synthesis and 
lipids for membrane synthesis to sustain rapid division. Similarly, 
one may also ask why antioxidants are needed by cancer cells. And 
this is due to cancer cells experiencing increased oxidative stress 
caused by various factors such as hypoxia, mitochondrial muta-
tions, and aberrant signaling pathways that cause activated meta-
bolic machineries (2). Low levels of ROS act to signal the activation 
of oncogenic pathways such as MAPK, ERK, JNK, Akt, and HIF 
(3). Low levels of ROS also promote DNA mutations and genomic 
instability, supporting transformation (4). Conversely, high levels 
of ROS irreversibly damage cellular components, causing cell cycle 
arrest and apoptosis (3). Cancer cells need higher antioxidant-pro-
ducing capacity that enables them to survive oxidative stress (5, 6). 
Many conventional chemotherapies and radiotherapies eradicate 
cancer cells through ROS induction (7).
The folate cycle is an important metabolic pathway that ful-
fills a number of cancer-specific nutrient demands. Folate (folic 
acid), or vitamin B, is commonly found in Western diets and 
dietary supplements. A 1-carbon (1C) unit from serine is trans-
ferred to tetrahydrofolate (THF) by serine hydroxymethyl trans-
ferases (SHMTs) to form 5,10-methylenetetrahydrofolate (CH2-
THF). The 1C unit is then transferred from one position of THF to 
another, thus creating the folate cycle (Figure 1). The folate cycle 
is composed of the cytoplasmic and mitochondrial compartments. 
The cytoplasmic compartment is carried out by methylenetetra-
hydrofolate dehydrogenase, cyclohydrolase, and formyltetra-
hydrofolate synthetase 1 (MTHFD1), while the mitochondrial 
compartment is carried out by MTHFD2/2L and methylenetet-
rahydrofolate dehydrogenase 1–like (MTHFD1L). MTHFD1 is a 
cytoplasmic trifunctional enzyme with CH2-THF dehydrogenase, 
5,10-methenyl- tetrahydrofolate (CH+-THF) cyclohydrolase, and 
10-formyl-tetrahydrofolate (10-CHO-THF) synthase activities 
responsible for cytoplasmic reactions 1, 2, and 3 denoted in Fig-
ure 1, respectively. ALDH1L1, a 10-CHO-THF dehydrogenase, 
is responsible for reaction 4 denoted in Figure 1. MTHFD2/2L 
is a mitochondrial bifunctional enzyme with CH2-THF dehydro-
genase and CH+-THF cyclohydrolase activities responsible for 
mitochondrial reactions 5 and 6, respectively (Figure 1). Nota-
bly, MTHFD2 mainly uses NAD+ while MTHFD2L mainly uses 
NADP+ to generate NADH and NADPH, respectively. MTHFD1L 
is a mitochondrial monofunctional enzyme with 10-CHO-THF 
synthase activity responsible for reaction 7 (Figure 1). ALDH1L2, 
another 10-CHO-THF dehydrogenase, is responsible for reaction 
8. The exchange of THF molecules between the cytoplasmic and 
mitochondrial compartments is restricted. However, both com-
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growth delay, neural tube and craniofacial abnormalities, and 
embryonic lethality (12). In humans, MTHFD1L polymorphisms 
are closely related to neural tube defects, coronary artery disease, 
and Alzheimer’s disease (13–15). Two microarray gene expression 
profile studies briefly revealed that MTHFD1L was overexpressed 
in colorectal and breast cancers (16, 17). Discovered in breast 
cancer cells, miR-9 and miR-197 inhibited MTHFD1L through 
interacting with its 3′-UTR (18, 19). A recent metastudy includ-
ing microarray data from more than 1,900 tumor tissues of 19 
different cancer types suggested that the mitochondrial 1-carbon 
metabolism is the most deregulated metabolic pathway in human 
cancers (20). Intriguingly, SHMT2 and MTHFD2 were found to 
be overexpressed in multiple human cancers and were correlated 
with shorter survival in breast cancer patients (16, 20, 21). Knock-
down of MTHFD2 in breast cancer cells suppressed proliferation 
and induced apoptosis (20). Multiple studies indicated that the 
folate cycle is an important metabolic pathway crucial to cancer 
growth (11, 20, 22–24). A recent study showed that the folate cycle, 
through NADPH production, enabled melanoma cells to endure 
oxidative stress during metastasis (25).
Hepatocellular carcinoma (HCC), a malignancy transformed 
from hepatocytes, accounts for 90% of primary liver cancers. 
HCC is the fifth most common and second most fatal cancer 
worldwide. Owing to late symptom presentation, most HCC 
patients are diagnosed at advanced stages when surgical treat-
ments are deemed unsuitable. Currently, the only FDA-approved 
targeted therapy for HCC patients, a multikinase inhibitor known 
as sorafenib, prolongs their lifespan for a mere 3 months (26, 27). 
A better therapeutic regimen is warranted. The liver is a meta-
partments are intimately linked by the transportation of serine, 
glycine, and formate across the mitochondrial membrane (Figure 
1). The continuous cyclical movements in 2 compartments gener-
ate many metabolites essential for cell growth. The cytoplasmic 
folate cycle intermediate 10-CHO-THF is required for purine syn-
thesis, while CH2-THF is required for deoxythymidine monophos-
phate (pyrimidine) synthesis. CH2-THF is converted to CH3-THF 
by methylenetetrahydrofolate reductase (MTHFR). CH3-THF is 
then connected to the methionine cycle, where the 1C unit from 
CH3-THF is donated to homocysteine, generating methionine, the 
donor of S-adenosylmethionine for DNA and histone methylation. 
Importantly, the folate cycle is an important source of NADPH (8), 
a major cellular antioxidant. Stable isotope tracing experiments 
have demonstrated that a majority of 1C units (>75%) entering the 
cytoplasmic methionine cycle were derived from the mitochon-
dria, further confirming the connection of 2 compartments (9). 
MTHFD1L is the enzyme catalyzing the last step of the mitochon-
drial compartment generating formate and could subsequently 
enter the cytoplasmic compartment. MTHFD1L therefore plays 
critical roles in folate cycle maintenance (10).
Despite the importance of MTHFD1L in the folate cycle, 
knowledge about its roles in human diseases, especially cancer, 
remains largely elusive. Farber made the first observation in 1949 
that leukemic cell growth was stimulated by folic acid while folic 
acid antagonists resulted in temporary remissions in patients 
with acute leukemia (11). His important discovery on the roles of 
folate in cancer provided the foundation of the development of 
chemotherapeutic agents as single or combined treatments for 
cancer (11). Homozygous Mthfd1l-knockout mice exhibited fetal 
Figure 1. The folate cycle in cancer. Cytosolic and mitochondrial compartments of the folate cycle generate many key metabolites for cell growth.
Downloaded from http://www.jci.org on October 4, 2017.   https://doi.org/10.1172/JCI90253
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 5 8 jci.org   Volume 127   Number 5   May 2017
Figure 2. The folate cycle in cancer. (A) An HCC cell line, MHCC97L, was cultured in complete MEM (2 μM folate) and folate-free MEM, and cell numbers 
were recorded by cell counter. (B) Different HCC cell lines, MHCC97L, PLC/PRF/5, Huh7, HepG2, and Hep3B, were cultured in MEM containing differ-
ent concentrations of folate, and BrdU uptake was recorded. (C) MTHFD1L mRNA expression in 16 cases of human HCC and paired nontumorous liver 
(NT) tissues was detected by transcriptome (RNA) sequencing. FPKM, fragments per kilobase of exon per million fragments mapped; HKU, University 
of Hong Kong. (D) Left: MTHFD1L mRNA expression in 85 cases of human HCC and paired NT tissues was detected by reverse transcription quantita-
tive PCR (RT-qPCR). Values were calculated based on the following formula: 2–(Ct of MTHFD1L – Ct of 18S), where Ct is the cycle threshold. Right: Waterfall plot 
demonstrated that MTHFD1L overexpression was found in 50.59% (43/85) of HCC cases. (E) MTHFD1L mRNA expression in 49 human HCC cases from 
TCGA. RSEM, RNA-Seq expression estimation by expectation maximization. (F) Analysis of TCGA data revealed that HCC patients with high MTHFD1L 
expression (Z score > 1) were significantly associated with poorer overall and disease-free survival. (G) MTHFD1L protein expression in 3 representa-
tive HCC cases. (H) MTHFD1L mRNA expression in 8 other solid cancers from the TCGA database. A and B: Results are representative of 3 independent 
experiments. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. folate depletion control. A, C, D, and H: Student’s t test. B: 1-way 
ANOVA. E: Wilcoxon signed-rank test. F: Kaplan-Meier followed by log-rank test.
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supporting HCC growth (Figure 2B). To gain insights on the clinical 
significance of the folate cycle in human HCC, we examined the 
expression of folate cycle enzymes by transcriptome sequencing 
in 16 pairs of human HCC and nontumorous liver tissues. Intrigu-
ingly, transcriptome sequencing in a small cohort of HCC patients 
revealed that a critical enzyme connecting the mitochondrial and 
cytoplasmic compartments of the folate cycle, MTHFD1L, was 
significantly overexpressed in HCC (Figure 2C). We confirmed 
MTHFD1L overexpression in an expanded cohort of 85 HCC 
patients by reverse transcription quantitative PCR (Figure 2D). 
MTHFD1L overexpression was present in 50.59% (43/85) of HCC 
patients by at least 2-fold (Figure 2D). HCC transcriptome sequenc-
ing data available in The Cancer Genome Atlas (TCGA) echoed 
our findings from in-house expression data (Figure 2E). From our 
in-house HCC samples, we found that MTHFD1L overexpression 
was closely associated with aggressive clinicopathological features 
of HCC including the presence of tumor microsatellite formation, 
venous invasion, and more advanced tumor stages (Table 1). TCGA 
data revealed that HCC patients with high MTHFD1L expression 
also have lower overall and disease-free survival rates (Figure 2F). 
Western blotting further confirmed that MTHFD1L was also over-
expressed at the protein level (Figure 2G). Apart from HCC, data 
retrieved from TCGA also revealed that MTHFD1L overexpression 
is present in solid cancers including esophageal cancer, stomach 
adenocarcinoma, bladder cancer, lung adenocarcinoma, breast 
cancer, colon adenocarcinoma, kidney renal cell carcinoma, and 
prostate adenocarcinoma (Figure 2H).
MTHFD1L is a transcription target of NRF2. Next, we inves-
tigated the possible molecular mechanisms driving MTHFD1L 
overexpression in HCC. A study using lung cancer cells showed 
that MTHFD2 expression was reduced upon knockdown of nucle-
ar factor (erythroid-derived 2)–like 2 (NRF2), a transcription fac-
tor that acts as the central regulator for redox homeostasis (28). 
We speculated that MTHFD1L is also a transcriptional target of 
NRF2. NRF2 expression is tightly regulated by kelch-like ECH-
associated protein 1 (KEAP1), a negative regulator that targets 
NRF2 for proteosomal degradation (29). Oxidative stress pre-
vents KEAP1-mediated degradation of NRF2, allowing the trans-
location of stabilized NRF2 into the nucleus, thereby binding 
to genes encompassing antioxidant response elements (AREs) 
5′-TMAnnRTGAYnnnGCRwwww-3′ (M = A/C, R = A/G, Y = C/T, 
w = A/T, and n = random bases) (29). NRF2 initiates transcrip-
tion of genes that counteract oxidative stress. We found 3 puta-
tive AREs in MTHFD1L and confirmed that NRF2 bound to these 
AREs by ChIP assay in a human HCC cell line, MHCC97L (Fig-
ure 3A). We generated NRF2-overexpressing MHCC97L cells by 
CRISPR-dCas9 Synergistic Activation Mediator (SAM) system 
and found that MTHFD1L mRNA expression was significantly 
induced (Figure 3B). Reversely, MTHFD1L mRNA and protein 
expressions were reduced upon knockdown of NRF2 in different 
HCC cell lines, MHCC97L, PLC/PRF/5, and Huh7 (Figure 3, C 
and D). These data converged to show that MTHFD1L is tran-
scriptionally regulated by NRF2.
Knockdown of MTHFD1L impedes HCC proliferation through 
induction of oxidative stress and ROS-associated cell cycle delay. 
To understand the functions of MTHFD1L, we generated 
MTHFD1L-overexpressing MHCC97L cells using CRISPR-
bolic organ responsible for a number of unique metabolic func-
tions, such as blood glucose homeostasis. During HCC develop-
ment, a series of liver-specific metabolic functions are impaired, 
accompanied by the acquisition of new metabolic traits that sup-
port the infinite growth of HCC cells. Thorough understanding of 
the metabolic machinery of HCC and its molecular basis is criti-
cal to the design of novel diagnostic and therapeutic approach-
es. In this study, using HCC as a cancer model, we demonstrate 
the indispensable roles of the folate cycle in cancer progression. 
Furthermore, we show that a pivotal enzyme of the folate cycle, 
MTHFD1L, is frequently overexpressed in cancers and confers 
on cancer cells the ability to survive oxidative stress–induced cell 
cycle delay and apoptosis. Blockade of the folate cycle by knock-
down or knockout of MTHFD1L or by the use of folate analog 
effectively represses cancer growth and sensitizes cancer cells 
toward sorafenib treatment.
Results
MTHFD1L in the folate cycle is significantly overexpressed in human 
cancers. To understand whether HCC cell proliferation relies on 
the folate cycle, we cultured an HCC cell line, MHCC97L, in com-
plete medium and folate-depleted medium. Depletion of folate 
significantly impaired the proliferation rate of MHCC97L (Figure 
2A). To confirm that this observation was not cell line–specific, 
we performed BrdU proliferation assay in MHCC97L as well as 4 
additional HCC cell lines, PLC/PRF/5, Huh7, HepG2, and Hep3B. 
Folate depletion significantly reduced BrdU uptake in different 
HCC cell lines, further suggesting folate as an important nutrient 
Table 1. Clinicopathological correlation of MTFHD1L upregulation 
in HCC patients
MTHFD1L expression
Normal Upregulation P value
Gender Male 38 26 0.290
Female 15 5
HBsAg Positive 41 26 0.775
Negative 11 5
Cirrhosis Present 25 18 0.366
Absent 26 12
Tumor size <5 cm 21 10 0.485
≥5 cm 29 20
Venous invasion Present 23 22 0.020A
Absent 28 8
Tumor microsatellite Present 20 20 0.037A
Absent 30 10
Direct liver invasion Present 18 12 0.806
Absent 28 15
Tumor encapsulation Present 18 8 0.464
Absent 32 22
Edmonson grading I/II 29 11 0.105
III/IV 21 19
pTNM staging I/II 25 7 0.021A
III/IV 26 24
AP < 0.05; n = 85; categorized based on 4-fold expression. pTNM, 
pathological tumor node metastasis.
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the metabolic vulnerabilities created by MTHFD1L knockdown 
would affect the proliferative output of HCC cells in vitro. As 
anticipated, knockdown and knockout of MTHFD1L significant-
ly repressed proliferation of MHCC97L cells (Figure 5C and Sup-
plemental Figure 1B). To confirm that our observation was not 
cell line–specific, we generated MTHFD1L-knockdown clones 
in 3 additional HCC cell lines, PLC/PRF/5, HepG2, and Hep3B 
(Supplemental Figure 2). Consistently, we found that knockdown 
of MTHFD1L caused ROS accumulation and repressed HCC 
proliferation in multiple HCC cell lines. We proceeded to ask 
whether ROS accumulation caused by MTHFD1L knockdown 
affects the cell cycle profile of HCC cells. HCC cells were first 
synchronized with nocodazole in the G2/M phase (Supplemental 
Figure 3). Cells were then released from nocodazole treatment. 
Propidium iodide staining showed that a greater percentage of 
MTHFD1L-knockdown and -knockout cells remained in the G1 
phase relative to nontarget control (NTC) cells (Figure 5, D and 
E; Supplemental Figure 1C; and Table 2). Administration of dif-
ferent antioxidants, reduced glutathione (GSH and GSH-EE) 
and N-acetylcysteine (NAC), allowed the reentry of MTHFD1L-
knockdown cells into the S and G2/M phases (Figure 5, D and 
E). MTHFD1L-mediated cell cycle delay was thus confirmed to 
be caused by ROS accumulation. We further confirmed that GSH 
could reduce ROS accumulation in MTHFD1L-knockdown cells 
(Figure 5F). BrdU proliferation assay further showed that GSH 
could partially rescue the proliferative deficiency of MTHFD1L-
knockdown HCC cells (Figure 5G).
dCas9 SAM system (Figure 4A). As a result of MTHFD1L over-
expression, we found that MTHFD1L increased the intracellular 
NADPH/NADP+ ratio and reduced intracellular ROS level (Fig-
ure 4, B and C). Reversely, we also generated MTHFD1L-knock-
down MHCC97L cells (Figure 4D) and found that knockdown of 
MTHFD1L reduced the intracellular NADPH/NADP+ ratio, lead-
ing to the accumulation of ROS (Figure 4, E and F). Knockout of 
MTHFD1L by CRISPR-Cas9 gene editing system in MHCC97L 
and PLC/PRF/5 cells consistently reduced the intracellular 
NADPH/NADP+ ratio and increased intracellular ROS level (Fig-
ure 4, G–L). ROS induces DNA damage by incorporating into the 
DNA of the cells to form 8-hydroxy-2-deoxyguanosine (8-OH-
dG). We found that DNA of the MTHFD1L-knockdown and 
-knockout cells contained a higher level of 8-OH-dG (Figure 5A 
and Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI90253DS1). 
Next, we evaluated the mitochondrial functions of MTHFD1L-
knockdown cells by the XFp Cell Mito Stress Test, in which oligo-
mycin, FCCP, and antimycin A and rotenone were sequentially 
added to the cells. As these drugs target different parts of the 
electron transport chain, oxygen levels detected at different drug 
injection time points generate a mitochondrial respiration pro-
file that reflects the mitochondrial activity (Figure 5B). Notice-
able reductions of basal respiration (oxygen consumption) and 
respiratory chain capacity as a result of MTHFD1L knockdown 
indicated the importance of MTHFD1L in maintaining proper 
mitochondrial function (Figure 5B). We further asked whether 
Figure 3. Regulation of MTHFD1L. (A) Top: Three AREs are located in MTHFD1L. Bottom: ChIP assay using NRF2 and IgG antibodies in MHCC97L cells confirmed 
that NRF2 bound to the putative AREs of MTHFD1L. (B) NRF2-overexpressing (OE) HCC cells were established by CRISPR-dCas9 SAM system. MTHFD1L and 
NRF2 mRNA expressions in MHCC97L–empty vector (EV), MHCC97L–nontarget control (NTC), and NRF2-OE HCC cells were detected by RT-qPCR and normalized 
to 18S. (C) NRF2-knockdown HCC cells were established by an shRNA approach. MTHFD1L and NRF2 mRNA expressions in PLC/PRF/5-NTC and PLC/PRF/5-
shNRF2 cells were quantitated by RT-qPCR and normalized to 18S. (D) NRF2 and MTHFD1L protein expressions in various NRF2-knockdown (MHCC97L-NTC, 
-shNRF2; PLC/PRF/5-NTC, -shNRF2; Huh7-NTC, -shNRF2) HCC cells. Band intensities were quantitated by ImageJ (NIH) and normalized to β-actin. A–C: Results 
are representative of 3 independent experiments. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC or EV. Student’s t test.
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Figure 4. MTHFD1L increased NADPH/NADP+ levels and reduced ROS. (A) MTHFD1L-overexpressing (OE) HCC cells were established by CRISPR-dCas9 
SAM system. mRNA and protein expressions of MTHFD1L in MHCC97L-MTHFD1L-OE stable cells that express single guide RNA (sgRNA) targeting 
MTHFD1L and MHCC97L-NTC stable cells that express nontarget control (NTC) sgRNA. (B) Levels of NADPH/NADP+ in MHCC97L-NTC and -MTHFD1L-
OE cells. (C) Levels of intracellular ROS in MHCC97L-NTC and -MTHFD1L-OE cells. (D) MTHFD1L-knockdown HCC cells were established by shRNA 
approach. mRNA and protein expressions of MTHFD1L in MHCC97L-NTC, -shMTHFD1L-00 (shML-00), and -shMTHFD1L-99 (shML-99) stable cells. 
(E) Levels of NADPH/NADP+ in MHCC97L-NTC, -shML-00, and -shML-99 stable cells. (F) Levels of intracellular ROS in MHCC97L-NTC, -shML-00, and 
-shML-99 stable cells. (G) MTHFD1L-knockout (KO) MHCC97L cells were established by CRISPR-Cas9 system. MTHFD1L protein expression in MHCC97L 
stable cells expressing empty vector control (EV) and sgRNA against MTHFD1L (ML-KO). (H) Levels of NADPH/NADP+ in MHCC97L-EV and -MTHFD1L-
KO (ML-KO) stable cells. (I) Levels of intracellular ROS in MHCC97L-EV and -ML-KO cells. (J) MTHFD1L-knockout (KO) PLC/PRF/5 cells were established 
by CRISPR-Cas9 system. MTHFD1L protein expression in PLC/PRF/5 stable cells expressing empty vector control (EV) and sgRNA against MTHFD1L 
(ML-KO). (K) Levels of NADPH/NADP+ in PLC/PRF/5-EV and MTHFD1L-KO (ML-KO) stable cells. (L) Levels of intracellular ROS in PLC/PRF/5-EV and 
-ML-KO cells. Results are representative of 3 independent experiments. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC 
or EV. A–C, H, I, K, and L: Student’s t test. D–F: 1-way ANOVA.
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Knockdown of MTHFD1L alters the metabolic program of HCC 
cells. To perceive the metabolic impacts of MTHFD1L on can-
cer cells, metabolomic profiling using capillary electrophoresis 
time-of-flight mass spectrometry (CE-TOFMS) was performed 
on MHCC97L-NTC and -shMTHFD1L cells (Supplemental 
Figure 4). Knockdown of MTHFD1L greatly altered the meta-
bolic profiles of HCC cells (Supplemental Figure 4A). Principal 
component analysis demonstrated that the extractions were 
consistent in the triplicates of each group (Supplemental Figure 
4B). Strikingly, the knockdown of MTHFD1L caused accumu-
lations of glyceraldehyde 3-phosphate (G3P), 3-phosphoserine 
(3PSer), and serine. As a serine molecule is required to initiate 
the folate cycle (Figure 6A), MTHFD1L knockdown resulted in 
the truncation of the folate cycle, thus blocking the transfer of a 
carbon unit from serine to THF, ultimately causing an accumu-
lation of serine and 3PSer (Figure 6B).
Interestingly, the glycolytic intermediates glucose 1-phos-
phate, glucose 6-phosphate, fructose 6-phosphate, fruc-
tose 1,6-bisphosphate, pyruvate, and lactate accumulated in 
MTHFD1L-knockdown HCC cells, suggesting a coordination 
between the folate cycle and glycolysis (Figure 6B). Another nota-
bly interesting pattern of metabolic changes in the TCA cycle was 
observed in the MTHFD1L-knockdown HCC cells (Figure 6C). We 
found that the levels of TCA cycle metabolic intermediates derived 
from pyruvate/acetyl-CoA, including citrate, cis-aconitate, and 
isocitrate, decreased (Figure 6D). Meanwhile, the levels of TCA 
Figure 5. Knockdown of MTHFD1L caused cell cycle delay. (A) 8-OH-dG levels in MHCC97L-NTC, -shML-00, and -shML-99 cells. (B) Oxygen consumption 
rate (OCR) in MHCC97L-NTC and -shML-99 cells was determined by XFp Analyzer (Seahorse Bioscience). Basal respiration, respiratory capacity, proton leak, 
and ATP-linked respiration were calculated based on the OCRs at different points when oligomycin, FCCP, and antimycin A and rotenone were sequen-
tially added to cells. (C) Cell proliferation rate of MHCC97L-NTC, -shML-00, and -shML-99. An equal number of cells was seeded on day 0. Cell numbers 
were recorded daily by cell counting. (D) Representative pictures of flow cytometry analyses of propidium iodide staining in MHCC97L-NTC, -shML-00, 
and -shML-99 stable cells that were synchronized by 200 ng/ml nocodazole for 16 hours and released for 9 hours in the presence of vehicle control and 
antioxidants 10 μM GSH, 0.1 mM GSH-EE, and 2 mM NAC. (E) Percentage of cells in G1 phase. (F and G) Levels of intracellular ROS (F) and BrdU uptake (G) 
in MHCC97L-NTC and -shML-99 cells treated with vehicle or different concentrations of reduced GSH. Results are representative of 3 independent experi-
ments. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC, or as indicated. A, C, and E–G: 1-way ANOVA. B: Student’s t test.
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from MHCC97L-NTC cells were more aggressive than those 
derived from MHCC97L-shMTHFD1L cells. Many of the tumors 
derived from the inoculation of MTHFD1L-knockdown cells were 
encapsulated and regular, while all tumors derived from control 
HCC cell inoculation exhibited invasive tumor growth fronts (Fig-
ure 8C and Table 3). Furthermore, many necrotic regions could 
be found in the tumors derived from the MTHFD1L-knockdown 
cells, suggesting that MTHFD1L-knockdown HCC cells could 
not survive as well as the control HCC cells. In line with the in 
vitro data, we found that HCCs with knockdown of MTHFD1L 
were more sensitive to sorafenib in a subcutaneous tumor model 
(Figure 8, D–F). Next, we investigated whether pharmacologi-
cal inhibition of the folate cycle by MTX would sensitize HCC 
cells to sorafenib treatment. MTX worked synergistically with 
sorafenib to suppress the growth of subcutaneous HCC tumors 
derived from MHCC97L as well as patient-derived tumor xeno-
grafts in nude mice (Figure 9, A–F). To further confirm our obser-
vation in immune-competent mice, we orthotopically implanted 
a mouse HCC cell line (Hepa 1-6) derived from C57BL/6 mouse 
background into the livers of C57BL/6 mice. Consistently, we 
observed synergism between MTX and sorafenib (Figure 9, G 
and H). MTX and sorafenib treatments are well tolerated in mice 
(Supplemental Figure 6), highlighting the translational value of 
this new therapeutic regimen for HCC patients.
Discussion
Over the past decade, research efforts have been devoted to under-
standing the metabolic advantages of the Warburg effect. Extensive 
studies focused on particularly the molecular alterations that drive 
the metabolism of glucose, the major nutrient and participant of the 
Warburg effect. On the other hand, folate, a major precursor for the 
folate cycle belonging to the 1-carbon metabolism, received very 
little attention. The folate cycle is critical for maintenance of various 
biological events, such as epigenetic modifications, nucleotide syn-
thesis, and antioxidant productions. Driven by our initial observa-
tion of growth impairment in folate-depleted HCC cells, we sought 
to understand the regulation and roles of the folate cycle in HCC 
development. In this study, we first demonstrated that the major 
function of the folate cycle in HCC cells is redox maintenance. We 
demonstrated that a crucial folate cycle component, MTHFD1L, was 
frequently upregulated in human cancers under the control of NRF2. 
Knockdown or knockout of MTHFD1L effectively reduced NADPH 
level and caused ROS accumulation and ROS-associated cell cycle 
delay, as well as HCC growth hindrance in vitro and in vivo.
cycle metabolic intermediates that could be derived from gluta-
mine, including α-ketoglutarate, succinate, fumarate, malate, and 
oxaloacetate, increased (Figure 6D). This suggested that gluta-
mine might replenish the TCA cycle to compensate for the effects 
of folate cycle defect. Unexpectedly, levels of nucleotides as well 
as methionine and its derivative S-adenosylmethionine were not 
decreased upon knockdown of MTHFD1L (Supplemental Figure 
5, A and B). NADPH is required for lipid synthesis, which supports 
HCC development (30–32). We performed Oil Red O staining to 
quantitate the levels of triglycerides and lipids in the MTHFD1L-
knockdown HCC cells and in HCC tumors treated with antifolate 
drug (methotrexate, MTX); however, no significant difference in 
lipid metabolism could be detected (Supplemental Figure 5, C and 
D). Our data suggested that the folate cycle is mainly used for oxi-
dative stress defense in HCC cells.
Inhibition of the folate cycle sensitizes HCC cells to sorafenib treat-
ment in vitro. Sorafenib is the only FDA-approved drug for HCC 
patients. Our next question was whether the inhibition of the folate 
cycle would sensitize HCC cells to sorafenib treatment. Sorafenib 
almost completely retarded the proliferation of MTHFD1L-knock-
down HCC cells (Figure 7A). Furthermore, oxidative stress was 
further elevated by sorafenib in the MTHFD1L-knockdown HCC 
cells (Figure 7B). More strikingly, sorafenib increased the percent-
age of apoptotic cells in the MTHFD1L-knockdown HCC cells 
(Figure 7C). To achieve folate cycle suppression through pharma-
cological inhibition, the effects of MTX in HCC were investigated. 
We found that MTX was able to act synergistically with sorafenib 
to suppress HCC cell proliferation in vitro (Figure 7D). Oxidative 
stress was also profoundly induced by sorafenib in MTX-treated 
cells (Figure 7E). Consistent with the knockdown of MTHFD1L, 
sorafenib significantly elevated apoptosis in HCC cells that were 
treated with MTX (Figure 7F).
Inhibition of the folate cycle represses HCC growth and sensitizes 
HCC cells to sorafenib treatment in vivo. To examine whether the met-
abolic defects elicited by MTHFD1L knockdown inhibit HCC pro-
gression in vivo, we performed orthotopic liver implantations with 
MHCC97L-NTC and -shMTHFD1L cells. Six weeks after implan-
tation, not only did we find that knockdown of MTHFD1L in HCC 
cells profoundly suppressed the growth of primary tumors (Figure 
8A); the incidence of lung metastasis was noticeably reduced (Fig-
ure 8B). Ex vivo imaging showed that lung metastasis was found in 
0 of 6 mice and 1 of 6 mice in the 2 MTHFD1L-knockdown groups 
as opposed to its occurrence in 5 of 6 mice from the NTC group 
(Figure 8B). Histological analysis suggested that tumors derived 
Table 2. P values between groups (percentage of cells in G1 phase)
Ctrl-NTC Ctrl-sh00 Ctrl-sh99 GSH-sh99 GSH-EE-sh99 NAC-sh99
Ctrl-NTC – <0.0001 0.0006 0.2464 1.0000 0.2464
Ctrl-sh00 – – 1.0000 0.0026 <0.0001 0.0026
Ctrl-sh99 – – – 0.0712 0.0002 0.0712
GSH-sh99 – – – – 0.0473 1.0000
GSH-EE-sh99 – – – – – 0.0473
NAC-sh99 – – – – – –
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phate pathway (PPP), was overexpressed in HCC owing to the 
inactivation of PTEN (33). Malic enzymes were overexpressed in 
human HCC (34) and were found to be repressed by p53 in osteo-
sarcoma cells (35). IDH mutations are frequent in cancers, and 
IDH mutants have altered enzymatic activities causing the con-
version of α-ketoglutarate to an oncometabolite, 2-hydroxygluta-
rate (36), leading to aberrant histone and DNA methylations in the 
cancer genome (37). Notably, all IDH mutations are heterozygous 
(38, 39), meaning the NADPH-producing ability of wild-type IDH 
NADPH serves as an antioxidant molecule by maintaining 
glutathione and thioredoxin in reduced states, allowing dona-
tion of their electrons to stabilize ROS. NADPH is produced by 
4 groups of enzymes: (a) glucose 6-phosphate dehydrogenase 
(G6PD), (b) malic enzymes, (c) isocitrate dehydrogenases (IDHs), 
and (d) MTHFDs. The first 3 groups of enzymes are tightly linked 
with glucose metabolism, and their involvements in cancer devel-
opment are well documented. However, little information could 
be found for MTHFDs. G6PD, a key enzyme in the pentose phos-
Figure 6. Knockdown of MTHFD1L caused serine accumulation. (A) Metabolic intermediates and reactions in glycolysis. (B) Quantification of metabolic 
intermediates in glycolysis and serine metabolism by CE-TOFMS. (C) Metabolic intermediates and reactions in TCA cycle. (D) Quantification of metabolic 
intermediates in TCA cycle by CE-TOFMS. G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; F1,6P, fructose 1,6-bisphosphate; G3P, glyceraldehyde 
3-phosphate; 3PG, 3-phosphoglycerate; 3PSer, 3-phosphoserine; α-KG, α-ketoglutarate. Values of all metabolites were normalized to NTC unless indicat-
ed. For 3PSer, absolute values from CE-TOFMS are shown in the graph, as no 3PSer could be detected in the NTC group, so values could not be normalized. 
Results are representative of 3 independent experiments. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC. Student’s t test.
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Figure 7. Genetic knockdown of MTHFD1L and pharmacological inhibition of the folate cycle sensitized HCC cells to sorafenib treatment via enhancing 
oxidative stress. (A) Proliferation of MHCC97L-NTC, -shML-00, and -shML-99 cells in the presence of vehicle control (Ctrl) and 2.5 μM sorafenib (Sor). (B) 
Representative flow cytometry analysis (left) and quantification (right) of ROS (CM-H2DCFDA) staining in MHCC97L-NTC and -shML-99 cells treated with 
vehicle control or 4 μM sorafenib for 24 hours. (C) Representative flow cytometry analysis (left) and quantification (right) of annexin V and propidium 
iodide staining in MHCC97L-NTC and -shML-99 cells treated with vehicle control or 4 μM sorafenib for 24 hours. (D) Proliferation of MHCC97L cells treated 
with vehicle control, 0.01 μM MTX alone, 4 μM sorafenib alone, and 0.01 μM MTX and 4 μM sorafenib (MTX+Sor). (E) Representative flow cytometry analy-
sis (left) and quantification (right) of ROS (CM-H2DCFDA) staining in MHCC97L cells treated with vehicle control, 0.01 μM MTX alone, 4 μM sorafenib alone, 
and 0.01 μM MTX and 4 μM sorafenib (MTX+Sor) for 24 hours. (F) Representative flow cytometry analysis (left) and quantification (right) of annexin V and 
propidium iodide staining in MHCC97L cells treated with vehicle control, 0.01 μM MTX alone, 4 μM sorafenib alone, and 0.01 μM MTX and 4 μM sorafenib 
(MTX+Sor) for 22 hours. Results are representative of 3 independent experiments. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 
Ctrl, Ctrl-NTC, or as indicated. 1-way ANOVA.
Downloaded from http://www.jci.org on October 4, 2017.   https://doi.org/10.1172/JCI90253
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 6 6 jci.org   Volume 127   Number 5   May 2017
induced by c-MYC under nutrient starvation and were crucial to 
HCC growth (40). Our metabolomics data confirmed that serine 
accumulated upon knockdown of MTHFD1L, suggesting that the 
folate cycle indeed coordinates with serine and glucose metabo-
lism to support cancer growth. A recent study showed that ATF4 
bound with NRF2 to transcriptionally activate PHGDH, PSAT, and 
PSPH (41). It is possible that MTHFD1L knockdown elevated ROS, 
which further stabilized NRF2, leading to the ATF4-associated 
activation of serine biosynthetic enzymes and subsequently ser-
ine accumulation. Another study showed that mTORC activated 
ATF4 for the transcription of MTHFD2 (42). The transcriptional 
program of ATF4 in HCC and its roles in HCC metabolism will be 
further explored in the future.
Interestingly, serine and glycine synthesis results in the pro-
duction of glutathione, a tripeptide of glycine, glutamate, and 
cysteine (43). It was thus expectedly reported that knockdown of 
is retained. Our report provides clear evidence that cancer cells 
rely on folate-derived NADPH. Consistent with the computational 
analysis predicting that the largest proportion of NADPH (~40%) 
in human proliferating cells comes from the folate cycle (8), our 
study confirms that the folate cycle plays a major role in oxidative 
stress defense in cancer while introducing an essential metabolic 
pathway for cancer growth.
Initiation of the folate cycle begins when serine reacts with 
THF. Serine can be either taken up exogenously or synthesized de 
novo from glucose, the latter suggesting a connection between the 
folate cycle and glucose metabolic pathways. G3P derived from 
glucose through glycolysis is converted to 3-phosphoglycerate, 
which is later converted to serine through 3 enzymes: phospho-
glycerate dehydrogenase (PHGDH), phosphoserine aminotrans-
ferase (PSAT), and phosphoserine phosphatase (PSPH). A recent 
study showed that all the 3 serine biosynthetic enzymes were 
Figure 8. Knockdown of MTHFD1L suppressed HCC growth and sensitized HCC cells to sorafenib treatment in vivo. (A) Luciferase-labeled MHCC97L-NTC, 
-shML-00, and -shML-99 cells were orthotopically injected into nude mice (n = 6 mice per experimental group) and allowed to grow for 45 days. Left: Biolu-
minescent image of mice implanted with different stable cells. Middle: Representative picture of orthotopic xenografts. Right: Quantification of tumor size. 
(B) Lung tissues were removed from mice of the orthotopic liver implantation model for Xenogen imaging. Left: Bioluminescent image of lung tissues. Right: 
Quantification of luciferase intensities of HCC cells in lung tissues. (C) H&E staining of the orthotopic tumors showing HCC-liver boundaries as indicated by 
arrows. Necrotic areas are represented by asterisks. (D) Growth curves of subcutaneous xenografts derived from MHCC97L-NTC and -shML-99 cells in nude 
mice that were administered vehicle control (Ctrl) or 30 mg/kg/d sorafenib (Sor) (n = 6 mice per experimental group). (E) Representative pictures of subcu-
taneous xenografts. (F) Quantification of tumor mass. Error bars indicate mean ± SEM. **P < 0.01, ***P < 0.001 vs. NTC, Ctrl-NTC, or as indicated. 1-way 
ANOVA. A and E: scale bar, 1 cm; C: scale bar, 100 μm.
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mutations affect MTHFD1L expression and confer resistance to 
oxidative stress on HCC cells are also awaited.
Apart from NADPH, the folate cycle generates purine and 
pyrimidine; however, reduction of nucleotides in MTHFD1L-
knockdown HCC cells was not observed, despite a significant 
decrease in cancer growth. This is similar to our previous obser-
vation in PPP blockade (6). PPP is connected to glycolysis and is 
a major pathway that produces NADPH and ribose 5-phosphate 
(R5P), the backbone of DNA. Suppression of PPP in HCC through 
inhibition of transketolase reduced NADPH with no significant 
reduction in R5P but strongly inhibited HCC growth (6). Our pre-
vious study together with this current one strongly supports the 
notion that cancer cells have greater demands for antioxidants 
than building blocks to support primary cancer growth. A worth-
while study recently demonstrated that the folate cycle allowed 
melanoma cells to survive within the circulation and metasta-
size distantly (25). Our orthotopic liver implantation model has 
shown that the knockdown of MTHFD1L prominently reduced 
lung metastasis. However, it is unclear whether it was a second-
ary response due to reduced primary tumor growth. Metastatic 
efficiency of cancer cells could be further evaluated by tail-vein or 
splenic injection in the future.
Recently, Ducker et al. elegantly demonstrated that cells would 
compensate for the deficiency in the mitochondrial folate pathway 
by reversing the cytosolic 1C flux, suggesting flexibilities between 
the mitochondrial and cytosolic compartments of the folate cycle 
(24). Ducker et al. showed that blocking the mitochondrial folate 
pathway by knocking out MTHFD2, MTHFD1L, or SHMT2 using 
the CRISPR-Cas9 genome editing approach in cells inhibited the 
generation of 10-CHO-THF, making cells dependent on SHMT1 
for 1C unit production. They further showed that blocking SHMT1 
and MTHFD2 together could completely retard colorectal cancer 
growth. This important study provided an explanation as to why 
MTHFD1L knockdown or knockout alone could not achieve full 
HCC growth inhibition, as only the mitochondrial compartment 
is blocked. This might also explain why the effects of knockout 
are not as dramatic as those of knockdown, because MTHFD1L-
knockout cells might potentially be even more dependent on the 
cytoplasmic compartment than MTHFD1L-knockdown cells. A 
point worth mentioning is that NADPH from the mitochondrial 
compartment of the folate cycle is mainly produced by ALDH1L2, 
which competes with MTHFD1L for 10-CHO-THF. However, 
MTHFD1L is required for the production of formate, which could 
pass through the mitochondrial membrane. We further interrogat-
ed the ratios of these 2 enzymes in nontumorous and HCC tissues 
from the TCGA database. We found the MTHFD1L/ALDH1L2 
ratio elevated in HCC (Supplemental Figure 8), suggesting that 
more 10-CHO-THF might be used by MTHFD1L to generate for-
mate, which could sustain the continuity of the cytoplasmic com-
partment of the folate cycle in HCC. Another interesting point to 
note in the mitochondrial compartment of the folate cycle is that 
MTHFD2 and MTHFD2L compete for CH2-THF to make NADH 
and NADPH, respectively. TCGA data revealed that the mean val-
ues of the mRNA expression levels of MTHFD2 and MTHFD2L 
in HCC were 143.10 and 156.70, respectively (data not shown), 
suggesting that both enzymes are robustly expressed and both 
NADH and NADPH are required for HCC growth. The competi-
PSPH in HCC cells reduced glutathione production, which con-
sequently induced oxidative stress (40). Our current study indi-
cated that this elevation of oxidative stress might be related to the 
decline of serine entering the folate cycle, which would otherwise 
produce NADPH directly. Interestingly, the final and rate-limiting 
enzyme of serine biosynthesis, PSPH, was significantly upregu-
lated in human HCC (40). These reports echo in harmony with 
our findings of MTHFD1L overexpression in HCC patients, sug-
gesting that 1-carbon metabolism provides metabolic and survival 
advantages to HCC cells.
Our study provides evidence that MTHFD1L was regulated by 
the NRF2 pathway (44). The KEAP1/NRF2 pathway is the key path-
way providing defense against oxidative stress and is one of the 
most frequently mutated pathways in human HCC (44). Recently 
demonstrated in a hepatocarcinogen-induced HCC mouse mod-
el, NRF2 mutations were found to be present through all stages of 
HCC and could be detected in the majority of early preneoplastic 
lesions (45). Intriguingly, these mutations were found to be mis-
sense and located in the KEAP1-binding region (45). As KEAP1 
negatively regulates NRF2 expression through ubiquitin-proteo-
somal degradation, NRF2 mutations might result in stabilization 
of NRF2 that in turn activates antioxidant genes in HCC. TCGA 
data, however, revealed that KEAP1 and NRF2 mutations were 
found in only 4% and 3% of HCC samples, respectively (Supple-
mental Figure 7). These mutations were not significantly corre-
lated with high MTHFD1L expression in HCC patients (Supple-
mental Figure 7). A possible explanation for the extensive KEAP1/
NRF2 mutations in mouse models is that the hepatocarcinogen 
might have created DNA damage in the mouse livers. KEAP1/
NRF2 mutations should be further validated in other cohorts of 
HCC patients in the future. Functional characterization studies to 
directly and precisely elucidate which particular KEAP1 and NRF2 
Table 3. Aggressiveness of HCC tumors derived from  
MHCC97L-NTC, -shML-00, and -shML-99 cells
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ment in B-RAF– and K-RAS–associated lung cancers in mice (48). 
It was also shown that administration of the antioxidant NAC 
promoted melanoma cell metastasis (25). However, the extent 
and stage of diseases at which dietary folate or other antioxidant 
intakes are deemed harmful to human health remain unclear. 
On the other hand, it has become apparent that antioxidant-
producing pathways are attractive therapeutic targets for cancer 
cells given their increased reliance on antioxidants. Recently, 
an elegant study showed that combined usage of glutathione 
and thioredoxin inhibitors could efficiently block cancer initia-
tion and growth in breast cancer model (5). Our current study 
has unequivocally showed that the inhibition of the folate cycle 
rendered cancer cells more sensitive to treatment with sorafenib, 
tion between MTHFD1L and ALDH1L2 as well as MTHFD2 and 
MTHFD2L in the folate cycle will be an exciting avenue to be 
investigated.
The human body cannot synthesize folate de novo; thus 
folate must be taken up from diets. Dietary folate has long been 
advocated as having anticancer effects. Earlier epidemiological 
studies showed that dietary folate reduced the risk of several can-
cers, including breast and colorectal cancer (46, 47). These ear-
lier studies were coherent with the traditional belief that ROS are 
protumorigenic. This long-standing concept, however, has been 
shaken by our renewed attention and expanding knowledge on 
cancer metabolism. A recent study showed that diet supplement-
ed with antioxidant vitamin E or NAC promoted cancer develop-
Figure 9. Inhibition of the folate cycle suppressed HCC growth and sensitized HCC cells to sorafenib treatment in vivo. (A) Growth curves of subcutane-
ous xenografts derived from MHCC97L HCC cells in nude mice that were administered vehicle control (Ctrl), 30 mg/kg/d sorafenib (Sor), or 1.5 mg/kg/d 
MTX, or coadministered both 30 mg/kg/d sorafenib and 1.5 mg/kg/d MTX (Sor+MTX) (n = 10 mice per experimental group). (B) Representative pictures of 
subcutaneous xenografts. (C) Quantification of tumor mass. (D) Growth curves of subcutaneous xenografts from patient-derived tumor xenograft (PDTX, 
PY003) in nude mice that were administered vehicle control, 30 mg/kg/d sorafenib, or 1.5 mg/kg/d MTX, or coadministered both 30 mg/kg/d sorafenib 
and 1.5 mg/kg/d MTX (Sor+MTX) (n = 4 mice per experimental group). (E) Representative pictures of subcutaneous xenografts. (F) Quantification of 
tumor mass. (G) Representative photo of tumors orthotopically injected with mouse Hepa 1-6 HCC cells in C57BL/6N immune-competent mice (syngeneic) 
administered either vehicle control, sorafenib (30 mg/kg/d), MTX (3 mg/kg/d), or a combination of both (Sor+MTX) for 7 days (n = 6 mice per experimental 
group). (H) Quantification of the tumor size. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Ctrl, or as indicated. 1-way ANOVA. B, 
E, and G: scale bar: 1 cm.
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tate cancer were retrieved from The Cancer Genome Atlas (TCGA) via 
the Broad GDAC Firehose (Broad Institute). Only the available paired 
samples with both solid tumors and nontumorous counterparts were 
included in the comparison study. Cases without matched nontumor-
ous tissues were excluded for this analysis. Comparisons were done 
with paired t test.
ChIP assay. ChIP assay was performed as we previously described 
(49). In brief, cells were fixed with 3.7% formalin (vol/vol) and then 
sonicated. Sheared DNA was incubated with antibodies against NRF2 
(anti-rabbit, catalog ab62352, Abcam) or IgG control (anti-rabbit, 
catalog sc-2027, Santa Cruz Biotechnology). DNA-protein-antibody 
complexes were incubated with Protein A/Salmon Sperm DNA Aga-
rose Beads (Thermo Fisher Scientific). Beads were washed sequential-
ly with gradients of salt buffer and eluted in 1% SDS/NaHCO3. ChIP 
DNA was analyzed with primers flanking the putative AREs. Primer 
sequences are provided in Supplemental Table 2.
Stable HCC cell establishment. HCC cell lines with stable knock-
downs were produced using a lentiviral-mediated approach as previ-
ously described (49–51). In short, pLKO.1-puro vectors encompassing 
shRNAs targeting MTHFD1L (shMTHFD1L), NRF2 (shNRF2), or a 
nontarget control were stably transfected into HCC cell lines. Puro-
mycin was used for the selection of HCC cells with stable expression 
of shRNAs. MTHFD1L- and NRF2-overexpressing cell lines were 
generated using CRISPR-dCas9 Synergistic Activation Mediator 
(SAM) system as previously described (52). dCas9-VP64, MS2-p65-
HSF1, and single guide RNAs (sgRNAs) targeting the promoters of 
MTHFD1L were transfected into MHCC97L cells with sequential len-
tiviral infections. Zeocin was used for the selection of HCC cells with 
stable expression of sgRNAs for the CRISPR-dCas9 SAM system. For 
MTHFD1L-knockout cell establishment, Cas9 and sgRNA were intro-
duced into MHCC97L and PLC cells through a lentiviral-mediated 
approach as previously described (53). Puromycin was used for the 
selection of HCC cells with stable expression of the sgRNAs for the 
CRISPR-Cas9 gene editing (KO) system. Sequences of all sgRNAs and 
shRNAs are provided in Supplemental Table 3.
Western blotting. Protein extraction was performed on clinical 
HCC specimens snap-frozen using liquid nitrogen before storage at 
–80°C, and on HCC cells using the radioimmunoprecipitation assay 
(RIPA) buffer supplemented with complete protease inhibitor (Roche) 
and PhosSTOP phosphatase inhibitor cocktails (Roche). Equal vol-
umes of protein lysates were separated using 10% (vol/vol) SDS-
PAGE, and transferred onto PVDF membranes (GE Healthcare). For 
immunoblotting, antibodies against MTHFD1L (anti-rabbit, catalog 
HPA029041, Abcam and Atlas Antibodies), NDUFA4 (anti-rabbit, 
catalog ab129752, Abcam), NRF2 (anti-rabbit, catalog 12721, Cell Sig-
naling Technology), and β-actin (anti-mouse, catalog A5316, Sigma-
Aldrich) were used.
Cell proliferation assays. Cell proliferation rates were measured 
using 2 different assays: cell counting and 5-bromo-2′-deoxyuridine 
(BrdU) colorimetric (Roche) assay. For proliferation rates determined 
by cell counting, 2 × 104 cells per well were plated onto 12-well cul-
ture plates. Cells were trypsinized and counted using the Z1 Particle 
Counter (Beckman Coulter) 24 hours after plating of cells, daily for 4 
days. For proliferation rates determined by BrdU assay, 1 × 104 cells per 
well were plated onto 96-well culture plates. BrdU labeling and colo-
rimetric measurements were performed 24 hours after plating of cells 
according to the manufacturer’s instructions (Roche).
the only FDA-approved targeted therapeutic agent for advanced 
HCC patients. As we show that MTHFD1L is overexpressed in 
multiple solid cancers, it will be appealing to investigate whether 
folate inhibitors could be used in combination with other exist-
ing therapies in other cancer types. As we begin to understand 
more about the metabolic vulnerabilities in cancer, development 
of more precise inhibitors that specifically target the associated 
molecules is under way.
Methods
Clinicopathological correlation analysis and survival analysis. Clinico-
pathological features of human HCC were correlated with MTHFD1L 
expression in clinical specimens. Correlation of the features, includ-
ing cellular differentiation, direct liver invasion, hepatitis B surface 
antigen, tumor encapsulation, tumor microsatellite formation, tumor 
size, and venous invasion, was performed using SPSS 20.0 software 
(IBM Corp.). Pathological tumor node metastasis (pTNM) tumor stag-
ing was analyzed and graded by a pathologist. Demographics of HCC 
patients from our center are summarized in Supplemental Table 1. 
Patient survival data of 442 HCC patients were obtained from TCGA 
cBioPortal. MTHFD1L expression in HCC patients was defined as 
high if the Z score was greater than 1, or otherwise low. Survival analy-
sis was determined by Kaplan-Meier followed by log-rank test.
Cell culture. HCC cell lines MHCC97L, PLC/PRF/5, Huh7, 
HepG2, Hep3B, and Hepa 1-6 were used. MHCC97L was a gift from 
Z.Y. Yang (Fudan University of Shanghai, Shanghai, China). HepG2, 
Hep3B, and Hepa 1-6 were obtained from American Type Culture Col-
lection (ATCC) and were cultured in DMEM–high glucose (DMEM-
HG) media supplemented with sodium pyruvate, unless indicated. 
PLC/PRF/5 and Huh7, both obtained from ATCC, were cultured with 
DMEM-HG, unless indicated. All culture media were supplemented 
with 10% FBS (all reagents from Gibco).
RNA extraction, reverse transcription PCR, and quantitative real-
time PCR. Total RNA was extracted from clinical specimens that were 
snap-frozen using liquid nitrogen prior to storage at –80°C, and HCC 
cell lines using the TRIzol reagent (Life Technologies). cDNA was syn-
thesized from purified RNA samples by reverse transcription using the 
GeneAmp PCR Reagent Kit (Applied Biosystems). Quantitative real-
time PCR amplifications of MTHFD1L and the internal control 18S 
were performed using the TaqMan Gene Expression Assay (Applied 
Biosystems) for clinical specimens and using the SYBR Green qPCR 
Master Mix (Applied Biosystems) with corresponding primers (Supple-
mental Table 2) for HCC cell lines.
Transcriptome sequencing. Transcriptome sequencing was per-
formed using 16 pairs of human HCC tissues and their adjacent non-
tumorous liver tissues. The poly(A)+ mRNA library was prepared using 
the TruSeq Stranded mRNA Sample Prep Kit (Illumina). Using Illu-
mina HiSeq2000 (Axeq Technologies), 100-bp paired-end sequenc-
ing was performed. Subsequent data analysis was performed by the 
TopHat-Cufflinks pipeline, and the resulting values were indicated 
by FPKM (fragments per kilobase of transcript sequence per million 
mapped reads).
The Cancer Genome Atlas. Transcriptome sequencing data using 
50 pairs of human HCC tissues and their adjacent nontumorous liver 
tissues as well as other solid cancers including esophageal cancer, gas-
tric adenocarcinoma, bladder cancer, lung adenocarcinoma, breast 
cancer, colon adenocarcinoma, kidney renal cell carcinoma, and pros-
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Animal experiments. Animal experiments were performed on 6- to 
8-week-old male BALB/cAnN-nu (nude) mice. For the orthotopic tumor 
model, 1 × 106 MHCC97L cells, luciferase-labeled, were resuspended in 
100% Matrigel (BD Biosciences) and injected into the left lobes of the 
livers of the nude mice. Drug administration began 1 week after inocu-
lation. At 6 weeks (42 days) after inoculation, tumor-bearing mice were 
administered 100 mg/kg D-Luciferin (PerkinElmer) via i.p. injections 
for bioluminescent imaging using the Xenogen IVIS 100 Imaging Sys-
tem (Xenogen). Livers and lungs were also harvested for ex vivo imag-
ing as well as 10% formalin fixation followed by H&E staining for his-
tological analysis. For the syngeneic model, 4 × 106 Hepa 1-6 cells were 
resuspended in 100% Matrigel and injected into the left lobes of the 
livers of 4- to 6-week-old male C57BL/6N mice. Four days after inocu-
lation, tumor-bearing mice were administered sorafenib, MTX, both, or 
vehicle controls for 7 days. Livers were harvested, and tumor volumes 
were measured using electronic caliper and calculated using the follow-
ing formula: tumor volume = length (mm) × width (mm) × height (mm) 
× 0.52. For subcutaneous tumor models, 1 × 106 MHCC97L cells were 
resuspended in 100 μl PBS and injected s.c. onto either flank of the nude 
mice. Tumor volumes were measured using an electronic caliper and 
calculated as mentioned above. Drug administration began 1 week after 
inoculation. For the patient-derived tumor xenograft model, 1 × 106 cells 
from an HCC patient (PY003) were resuspended in 100% Matrigel and 
injected s.c. into nude mice. Drug administration began 11 days after 
inoculation. Tumor volumes were measured using an electronic caliper 
and calculated as mentioned above.
Pharmacological studies. HCC cells were treated with pharmaco-
logical agents in vitro for cell proliferation assay, ROS measurement, 
cell cycle analysis, and cell apoptosis experiments. Sorafenib (LC Lab-
oratories) was dissolved in DMSO, while MTX (Sigma-Aldrich) was 
dissolved in H2O and 0.5% 4 M NaOH, and glutathione reduced ethyl 
ester (GSH-EE) (Cayman Chemical), l-glutathione reduced (GSH), 
and N-acetyl-l-cysteine (NAC) (both from Sigma-Aldrich) were all 
dissolved in H2O. Sorafenib and MTX were also administered via oral 
gavage and i.p. injections, respectively, in vivo daily.
Oil Red O staining. Staining of neutral triglyceride and lipids was 
performed on cultured cells and frozen sections from livers of HCC-
bearing mice using Oil Red O (Sigma-Aldrich) dissolved in isopropa-
nol. To stain cultured cells, 1 × 105 MHCC97L-NTC or -shML cells 
were seeded onto 6-well plates. Plated cells were fixed with 10% for-
malin before staining with Oil Red O working solution diluted with 
distilled water. After removal of the stain and several washes with 
distilled water, Oil Red O dye on the dried cells was eluted with 100% 
isopropanol. Relative amounts of neutral triglyceride and lipids were 
determined by OD measurements at 500 nm with 100% isopropa-
nol as blank. To stain for neutral triglyceride and lipids from livers of 
HCC-bearing mice, frozen sections were air-dried and fixed in forma-
lin. After rinsing with 60% isopropanol, frozen sections were stained 
in Oil Red O before another rinse with 60% isopropanol. Sections 
were stained with hematoxylin, rinsed with hard water, and finally 
mounted in aqueous mountant for imaging and microscope analysis.
Statistics. All statistical analyses were performed using GraphPad 
Prism 5.0 software (GraphPad Software Inc.) by either 1-way ANOVA 
with Bonferroni’s correction, Student’s t test, or Wilcoxon signed-rank 
test. All functional assay experiments are representations of at least 
3 independent experiments expressed as mean ± SEM. Statistical sig-
nificance was considered with a P value less than 0.05.
ROS, NADPH, and 8-OH-dG measurements. Intracellular ROS lev-
els were measured in equal amounts of HCC cells plated into 6-well 
dishes. Cells were trypsinized and washed with PBS before staining 
with 2 μmol/l chloromethyl-20,70-dichlorodihydrofluorescein diace-
tate (CM-H2DCFDA) oxidative stress indicator (Life Technologies) 
and analyzed using the FACSCanto II Analyzer (BD Biosciences) flow 
cytometer. Results were analyzed using FlowJo software (FlowJo). 
Intracellular NADPH/NADP+ ratios were determined in HCC cells 
using the NADP/NADPH Quantification Colorimetric Kit (BioVi-
sion) according to the manufacturer’s instructions. Briefly, equal 
amounts of plated HCC cells on 6-well dishes were trypsinized and 
subjected to extraction by 2 freeze/thaw cycles using the Extraction 
Buffer. Portions of the extracted samples were heated at 60°C for 30 
minutes to allow for NADP decomposition while the other portion was 
left on ice (unheated). Both portions of the sample then underwent 
NADP cycling through incubation with the Cycling Buffer for 5 min-
utes before reaction development with the NADPH Developer. Inten-
sities of the NADPH and NAPD signals were measured with a plate 
reader at an OD of 450 nm. The NADPH/NADP+ ratio was calculated 
as: (intensity of heated samples) / (intensity of unheated samples – 
intensity of heated samples). For 8-OH-dG assay, 5 × 104 MHCC97L-
NTC or -shMTHFD1L cells were seeded on 12-well plates, and DNA 
was extracted by phenol chloroform. Seven micrograms of DNA was 
added into an 8-OH-dG antibody–precoated ELISA plate (Abcam) and 
incubated at room temperature for 1 hour. The ELISA plate was subse-
quently washed and developed with substrates following the manufac-
turer’s protocol (Abcam).
Oxygen consumption rate analysis. Oxygen consumption was mea-
sured by XFp Cell Mito Stress Test according to the manufacturer’s pro-
tocol (Seahorse Bioscience). In brief, MHCC97L-NTC or -shMTHFD1L 
cells were seeded onto miniplates at 50% confluence. One micromolar 
oligomycin, 0.125–2 μM FCCP, and 0.5 μM rotenone and antimycin A 
were injected into wells at the indicated time points, and oxygen con-
tent was measured by XFp Analyzer (Seahorse Bioscience).
Cell cycle analysis. The analysis of cell cycle distributions was per-
formed using propidium iodide (PI) stain (Calbiochem) subjected to 
flow cytometric analysis. Briefly, cells were treated with nocodazole 
(200 ng/ml) for 16 hours for synchronization in the G2/M phase of 
the cell cycle. Nocodazole was removed from the cells after synchro-
nization for 9 hours before harvesting for fixation using 75% (vol/vol) 
ethanol for 1 hour. Cells were stained with 50 μg/ml PI for 30 minutes 
under incubation before analysis using the FACSCanto II Analyzer 
(BD Biosciences).
Cell apoptosis analysis. Cells were cultured in serum-free medium 
for 24 hours before trypsinization and subsequently resuspended 
in Annexin V binding buffer (BD Biosciences) with annexin V–FITC 
(MBL International) and PI (BD Biosciences) for staining at room tem-
perature for 15 minutes according to the manufacturer’s instructions. 
The percentage of cell apoptosis for each sample was analyzed with 
flow cytometry.
Metabolomics. MHCC97N-NTC or -shMTHFD1L cells were washed 
with 5% (wt/wt) mannitol and scraped with methanol in the presence of 
10 μM of internal control solution comprising compound C1 with m/z at 
182.048 and compound A1 with m/z at 231.070 (Human Metabolome 
Technologies). Supernatants were filtered by centrifuge filter unit and 
were evaporated by centrifugation. Extracted intracellular metabolites 
were analyzed by CE-TOFMS by Human Metabolome Technologies.
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